Prevalence and burden of carotid and femoral atherosclerosis in subjects older than 30 years-old without known cardiovascular disease determined by bidimensional vascular ultrasound

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
F Botto ◽  
S Obregon ◽  
A Di Leva ◽  
G Fischer Sohn ◽  
J.H Bang ◽  
...  

Abstract Introduction 2019 ESC guidelines on dyslipidemia (DLP) and diabetes (DM) recommend (class IIa) measurement of arterial (carotid and/or femoral) plaque burden with vascular ultrasound (VUS) as a risk modifier in individuals at low or moderate risk with DLP and in asymptomatic patients with DM. However, there are no standard thresholds to categorize atherosclerosis burden (AB) measured by 2D-VUS, a simple, safe and spread technology. Purpose To explore carotid (c) and femoral (f) plaques prevalence and AB according to age, sex and cardiovascular risk factors (CVRF) in subjects older than 30 years-old without known atherosclerotic cardiovascular disease (ASCVD) Methods Among 9,987 consecutive individuals self-referred or referred by physicians for a cardiovascular workup, we present a cross-sectional analysis of 5,775 first visits of those between 30 and 80 years-old without known ASCVD. We registered prospectively information about CVRF, lifestyle and anthropometrics and determined the prevalence of atherosclerotic plaques evaluating bilateral carotid and femoral arteries with 2D-VUS, applying the Mannheim Consensus definition. Further, we estimated c-AB as the sum of all carotid plaque areas (in mm2), and f-AB according to the presence of unilateral, bilateral or no femoral plaques. Median c-AB and 25–75th percentiles by age and sex were determined. We finally examined the association of AB with number of CVRF adjusted by age. Results 61% were men, mean age was 51.3 (SD 10.6) years. CVRF were hypertension 53.3%, dyslipidemia 50.3%, sedentarism 56.9%, obesity 28.2%, smoking 16.6% and diabetes 7.3%. Near 10% had no CVRF, 23.1% had 1, 29.8% had 2 and 37.4% had ≥3 CVRF. 42% were medicated on antihypertensives and 17.8% on lipid-lowering drugs. Globally, plaque prevalence was 51% in carotid arteries, 39.3% in femoral arteries, 62.4% in carotid or femoral arteries, and 37.6% in neither. There was an age-related increasing pattern in both sex, stepper in men compared to women before 50 years-old (see graph). Median cAB showed also increasing values with aging, starting at 40 years-old and being higher in men than women with nearly 8 to 10 years ahead of time. Likewise it was observed regarding the presence of uni and bilateral femoral plaques. Finally, there was an increasing prevalence of plaques by number of CVRF, higher in men than women, either in the whole population and in those younger than 50 years-old. However, plaques prevalence was elevated in subjects with 0 (44.9% in men and 35.2% in women) or 1 CVRF (59.2% in men and 44.4% in women), leveraged by age. Conclusions We observed a high prevalence of carotid or femoral atherosclerosis, higher in men than women, and a high AB in both sex, starting before the fourth decade of life and increasing with age. In spite of a significant association to classic CVRF, a significant number of subjects with paucity of CVRF were diagnosed with atherosclerosis Prevalence of carotid or femoral plaques Funding Acknowledgement Type of funding source: None

2021 ◽  
Author(s):  
Matthieu DIETZ ◽  
Christel H. Kamani ◽  
Emmanuel Deshayes ◽  
Vincent Dunet ◽  
Periklis Mitsakis ◽  
...  

Abstract BackgroundIntegrin alpha-V-beta-3 (αvβ3) pathway is involved in intraplaque angiogenesis and inflammation and represents a promising target for molecular imaging in cardiovascular diseases such as atherosclerosis. The aim of this study was to assess the clinical correlates of arterial wall accumulation of 68Ga-NODAGA-RGD, a specific αvβ3 integrin ligand for PET. Materials and methodsThe data of 44 patients who underwent 68Ga-NODAGA-RGD PET/CT scans were retrospectively analyzed. Tracer accumulation in the vessel wall of major arteries was analyzed semi-quantitatively by blood-pool-corrected target-to-background ratios. Tracer uptake was compared with clinically documented atherosclerotic cardiovascular disease, cardiovascular risk factors and calcified plaque burden. Data were compared using the Mann-Whitney U test and Spearman correlation. Results68Ga-NODAGA-RGD arterial uptake was significantly higher in patients with previous clinically documented atherosclerotic cardiovascular disease (mean TBR 2.44 [2.03-2.55] vs. 1.81 [1.56-1.96], p = 0.001) and showed a significant correlation with prior cardiovascular or cerebrovascular event (r = 0.34, p = 0.024), BMI (r = 0.38, p = 0.01), plaque burden (r = 0.31, p = 0.04), and hypercholesterolemia (r= 0.31, p = 0.04).Conclusions68Ga-NODAGA-RGD holds promise as a non-invasive marker of disease activity in atherosclerosis, providing information about intraplaque angiogenesis.


2017 ◽  
Vol 25 (4) ◽  
pp. 420-431 ◽  
Author(s):  
Jelena Pavlović ◽  
Philip Greenland ◽  
Jaap W Deckers ◽  
Maryam Kavousi ◽  
Albert Hofman ◽  
...  

Background The purpose of this study was to determine how American College of Cardiology/American Heart Association (ACC/AHA) 2013 and European Society of Cardiology 2016 guidelines for the primary prevention of atherosclerotic cardiovascular disease (CVD) compare in reflecting the totality of accrued randomised clinical trial evidence for statin treatment at population level. Methods From 1997–2008, 7279 participants aged 45–75 years, free of atherosclerotic cardiovascular disease, from the population-based Rotterdam Study were included. For each participant, we compared eligibility for each one of 11 randomised clinical trials on statin use in primary prevention of CVD, with recommendations on lipid-lowering therapy from the ACC/AHA and European Society of Cardiology (ESC) guidelines. Atherosclerotic cardiovascular disease incidence and cardiovascular disease mortality rates were calculated. Results The proportion of participants eligible for each trial ranged from 0.4% for ALLHAT-LLT to 30.8% for MEGA. The likelihood of being recommended for lipid-lowering treatment was lowest for those eligible for low-to-intermediate risk RCTs (HOPE-3, MEGA, and JUPITER), and highest for high-risk individuals with diabetes (MRC/BHF HPS, CARDS, and ASPEN) or elderly PROSPER. Eligibility for an increasing number of randomised clinical trials correlated with a greater likelihood of being recommended lipid-lowering treatment by either guideline ( p < 0.001 for both guidelines). Conclusion Compared to RCTs done in high risk populations, randomised clinical trials targeting low-to-intermediate risk populations are less well-reflected in the ACC/AHA, and even less so in the ESC guideline recommendations. Importantly, the low-to-intermediate risk population targeted by HOPE-3, the most recent randomised clinical trial in this field, is not well-captured by the current European prevention guidelines and should be specifically considered in future iterations of the guidelines.


F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 1402 ◽  
Author(s):  
Prediman K. Shah ◽  
Dalgisio Lecis

Atherosclerotic cardiovascular disease is a leading cause of death and morbidity globally. Over the past several years, arterial inflammation has been implicated in the pathophysiology of athero-thrombosis, substantially confirming what pathologist Rudolf Virchow had observed in the 19th century. Lipid lowering, lifestyle changes, and modification of other risk factors have reduced cardiovascular complications of athero-thrombosis, but a substantial residual risk remains. In view of the pathogenic role of inflammation in athero-thrombosis, directly targeting inflammation has emerged as an additional potential therapeutic option; and some early promising results have been suggested by the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS), in which canakinumab, a fully human monoclonal antibody targeting the pro-inflammatory and pro-atherogenic cytokine interleukin 1 beta, was shown to reduce cardiovascular events.


Circulation ◽  
2017 ◽  
Vol 135 (22) ◽  
pp. 2204-2206 ◽  
Author(s):  
Joshua W. Knowles ◽  
William B. Howard ◽  
Lala Karayan ◽  
Seth J. Baum ◽  
Katherine A. Wilemon ◽  
...  

Metabolites ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. 690
Author(s):  
Jennifer Behbodikhah ◽  
Saba Ahmed ◽  
Ailin Elyasi ◽  
Lora Kasselman ◽  
Joshua De Leon ◽  
...  

Apolipoprotein (apo) B, the critical structural protein of the atherogenic lipoproteins, has two major isoforms: apoB48 and apoB100. ApoB48 is found in chylomicrons and chylomicron remnants with one apoB48 molecule per chylomicron particle. Similarly, a single apoB100 molecule is contained per particle of very-low-density lipoprotein (VLDL), intermediate density lipoprotein, LDL and lipoprotein(a). This unique one apoB per particle ratio makes plasma apoB concentration a direct measure of the number of circulating atherogenic lipoproteins. ApoB levels indicate the atherogenic particle concentration independent of the particle cholesterol content, which is variable. While LDL, the major cholesterol-carrying serum lipoprotein, is the primary therapeutic target for management and prevention of atherosclerotic cardiovascular disease, there is strong evidence that apoB is a more accurate indicator of cardiovascular risk than either total cholesterol or LDL cholesterol. This review examines multiple aspects of apoB structure and function, with a focus on the controversy over use of apoB as a therapeutic target in clinical practice. Ongoing coronary artery disease residual risk, despite lipid-lowering treatment, has left patients and clinicians with unsatisfactory options for monitoring cardiovascular health. At the present time, the substitution of apoB for LDL-C in cardiovascular disease prevention guidelines has been deemed unjustified, but discussions continue.


2020 ◽  
Vol 15 ◽  
Author(s):  
Charles Amir German ◽  
Michael David Shapiro

Cardiovascular disease is the number one cause of death and disability worldwide. While substantial gains have been made in reducing cardiovascular mortality, future projections suggest that we have reached a nadir and may be at an inflection point, given the rising tide of obesity and diabetes. Evaluation and management of plasma lipids is central to the prevention of atherosclerotic cardiovascular disease. Although the standard lipid panel represents a well-established platform to assess risk, this test alone can be insufficient and/or misleading. Advances in our understanding of atherosclerosis have led to the development of lipid-based biomarkers that help to discriminate the risk of cardiovascular disease when it is unclear. While these biomarkers provide novel information, their implementation into clinical medicine remains difficult given discrepancies in the literature, lack of assay standardisation, poor accessibility and high cost. However, additional measures of atherogenic lipoproteins or their surrogates may offer insight beyond the standard lipid panel, providing a more precise assessment of risk and more accurate assessment of lipid-lowering therapy.


Sign in / Sign up

Export Citation Format

Share Document